WSTAM
PTLA

Wilbanks Smith & Thomas Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-250
Closed -$7K – 1489
2018
Q3 		$7K Buy
+250
New +$8.16K ﹤0.01% 1151

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's PTLA Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2018, closing a stake of 250 shares — an estimated $7K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in PTLA in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 181 funds tracked by Wall St. Rank hold PTLA as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 250 Portola Pharmaceuticals, Inc. shares in Q4 2018, an estimated $7K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Portola Pharmaceuticals, Inc. position peaked at $7K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.